ABSTRACT
Helicobacter pylori (Hp) infections pose a global health challenge demanding innovative therapeutic strategies by which to eradicate them. Urease, a key Hp virulence factor hydrolyzes urea, facilitating bacterial survival in the acidic gastric environment. In this study, a multi-methodological approach combining pharmacophore- and structure-based virtual screening, molecular dynamics simulations, and MM-GBSA calculations was employed to identify novel inhibitors for Hp urease (HpU). A refined dataset of 8,271,505 small molecules from the ZINC15 database underwent pharmacokinetic and physicochemical filtering, resulting in 16% of compounds for pharmacophore-based virtual screening. Molecular docking simulations were performed in successive stages, utilizing HTVS, SP, and XP algorithms. Subsequent energetic re-scoring with MM-GBSA identified promising candidates interacting with distinct urease variants. Lys219, a residue critical for urea catalysis at the urease binding site, can manifest in two forms, neutral (LYN) or carbamylated (KCX). Notably, the evaluated molecules demonstrated different interaction and energetic patterns in both protein variants. Further evaluation through ADMET predictions highlighted compounds with favorable pharmacological profiles, leading to the identification of 15 candidates. Molecular dynamics simulations revealed comparable structural stability to the control DJM, with candidates 5, 8 and 12 (CA5, CA8, and CA12, respectively) exhibiting the lowest binding free energies. These inhibitors suggest a chelating capacity that is crucial for urease inhibition. The analysis underscores the potential of CA5, CA8, and CA12 as novel HpU inhibitors. Finally, we compare our candidates with the chemical space of urease inhibitors finding physicochemical similarities with potent agents such as thiourea.
Subject(s)
Helicobacter pylori , Helicobacter pylori/metabolism , Urease/metabolism , Molecular Dynamics Simulation , Molecular Docking Simulation , Urea/pharmacologyABSTRACT
BACKGROUND: The clinical outcome of Helicobacter pylori (H. pylori) infection has been related to the presence of CagA protein. This protein is highly polymorphic and its oncogenic ability depends on the number and type of tyrosine phosphorylation sites in the EPIYAs repeat sequences (A, B, C and D). AIM: To determine the EPIYA patterns of the CagA gene in H. pylori strains and its relationship with gastrointestinal pathology in infected patients of the Regional Hospital of Talca. MATERIAL AND METHODS: The strains were isolated from gastric biopsies and characterized by bacteriological and molecular methods. Gastrointestinal pathology was characterized by histopathological analysis. For the determination of the presence of the cagA gene and the EPIYAs standards, the conventional PCR technique was used. RESULTS: 138 DNA samples from H. pylori strains were analyzed. 92.0% (127/138) of the isolates carried the cagA gene, of which 66 (52.0%) corresponded to the EPIYA-ABC pattern, 43 (33.8%) to the EPIYA-ABCC pattern and 21 16.5%) to the EPIYA-ABCCC phosphorylation pattern. 50.4% (64/127) of cagA positive strains isolated from dyspeptic patients in the Maule region have more than two C sites of phosphorylation. The number of EPIYAs C motifs was associated with the presence of more severe histopathological damage in the gastric mucosa.
